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Abstract
Macrophage-CSF (M-CSF) is critical for osteoclast (OC) differentiation and is reported to enhance mature OC survival and
motility. However, its role in the regulation of bone resorption, the main function of OCs, has not been well characterised.
To address this we analysed short-term cultures of fully differentiated OCs derived from human colony forming unit-
granulocyte macrophages (CFU-GM). When cultured on dentine, OC survival was enhanced by M-CSF but more effectively
by receptor activator of NFkB ligand (RANKL). Resorption was entirely dependent on the presence of RANKL. Co-treatment
with M-CSF augmented RANKL-induced resorption in a concentration-dependent manner with a (200–300%) stimulation at
25 ng/mL, an effect observed within 4–6 h. M-CSF co-treatment also increased number of resorption pits and F-actin sealing
zones, but not the number of OCs or pit size, indicating stimulation of the proportion of OCs activated. M-CSF facilitated
RANKL-induced activation of c-fos and extracellular signal-regulated kinase (ERK) 1/2 phosphorylation, but not NFkB nor
nuclear factor of activated T-cells, cytoplasmic-1 (NFATc1). The mitogen-activated protein kinase kinase (MEK) 1 inhibitor
PD98059 partially blocked augmentation of resorption by M-CSF. Our results reveal a previously unidentified role of M-CSF
as a potent stimulator of mature OC resorbing activity, possibly mediated via ERK upstream of c-fos.
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Introduction
The critical role of macrophage-colony stimulating factor (M-
CSF) in osteoclast (OC) differentiation from hematopoietic
precursors was demonstrated in mice with osteopetrosis due to
disruption of the CSF-1 gene (Csf1
op/Csf1
op). Osteoclasts were
completely absent in these mutant animals [1–5]. However, the
role of M-CSF in the function of fully-differentiated OCs, in
particular bone resorbing activity, is unclear. Two recent studies in
mice suggest a role for M-CSF in OC activation. Mice rendered
osteopetrotic, either by disruption of the CSF-1 gene (Csf1
op/
Csf1
op), or administration of a neutralizing anti-CSF-1 antibody,
displayed this high bone mass phenotype due to total lack, or
significant reduction in the number of OCs [6,7]. Partial
correction of osteopetrosis was achieved by either co-expression
of cell-surface M-CSF in the case of the Csf1
op/Csf1
op background,
or cessation of neutralizing anti-CSF-1 antibody administration. In
both cases there were equivalent levels of OCs to those seen in
control animals, leading the authors to deduce that the rate of
bone resorption in animals with sub-optimal levels of M-CSF was
slower.
In short-term (6 h) semi-pure cultures of isolated neonatal rat
OCs, human M-CSF enhanced survival, motility and cytoplasmic
spreading, but inhibited resorbing activity, in a concentration-
dependent manner; maximum effect at 0.5 ng/mL [8]. In
contrast, in 6–18 h cultures of isolated human fetal OCs, M-
CSF had no apparent effect on resorbing activity but did enhance
survival; maximum effect at 50 ng/mL [9]. Experiments in a
human bone marrow osteoclastogenesis assay suggested that
resorption per OC was enhanced in the presence of M-CSF
50 ng/mL [10]. Likewise, in an osteoclastogenesis assay employ-
ing human colony forming unit-granulocyte macrophage (CFU-
GM) precursors, we found that resorption per OC was increased
in the presence of M-CSF 25 ng/mL [11]. However, investigation
of resorbing activity in osteoclastogenesis assays is problematic
because of the confounding effects of proliferation, differentiation
and fusion. Furthermore, these findings were inconsistent with the
widely held view [12–16] that, in fully differentiated OCs, the role
of M-CSF is limited to regulation of survival and motility while
receptor activator of NFkB ligand (RANKL) and perhaps
interleukin-1 (IL-1) [17,18] are the key regulators of resorption
activation.
To address this knowledge gap, we established a mature OC
model based on that of Fuller and colleagues [17] that would allow
the characterization of the role of M-CSF in the short-term
regulation of resorption activation and survival in these cells. We
generated OCs en masse by treating CFU-GM-derived cells with
M-CSF and RANKL for 14d [19]. The OCs were then either
detached from the plastic and cultured on dentine slices for 4–72 h
for resorption and survival assays, or used in situ for transcription
factor activation and signalling phosphorylation assays. We
demonstrate that although RANKL is necessary for resorption,
M-CSF 10–25 ng/mL potently augments RANKL-induced re-
sorption, an effect that is not due to enhanced survival but, rather,
PLoS ONE | www.plosone.org 1 June 2011 | Volume 6 | Issue 6 | e21462due to increased activation of resorption in OCs. We also
demonstrate that M-CSF potentiates RANKL-induced c-fos
activation and extracellular signal-regulated kinase (ERK) 1/2
phosphorylation, and that the resorption-stimulating effect of M-
CSF is blocked by the mitogen-activated protein kinase (MEK)
inhibitor PD98059. This is the first study to definitively identify M-
CSF as a potent enhancer of resorption activation of mature OCs,
a paradigm-shift for its role in physiology and pathophysiology.
Materials and Methods
Materials
Eagle’s MEM, penicillin/streptomycin, paraformaldehyde, Sig-
ma Cell Dissociation Solution (1X) non-enzymatic (Cat.
No. C5914), Fast Garnett GBC, MEK1/2 inhibitor PD98059
and naphthol AS-BI-phosphate were purchased from Sigma. Non-
essential amino acids (100X) and FBS were purchased from
Bovogen (Melbourne, Australia). Ficoll-Paque was purchased from
Pharmacia Biotech. MethoCult GF H4534 (Iscove’s MDM
containing 1% methylcellulose, 30% FBS, 1% BSA, 10
24 M2 -
mercaptoethanol, 2 mM L-glutamine, 10 ng/ml recombinant
human GM-CSF, 10 ng/ml IL-3, and 50 ng/ml stem cell factor)
was purchased from Stem-Cell Technologies. Human M-CSF and
neutralising polyclonal antibody against M-CSF was purchased
from Chemicon. Primary rabbit monoclonal antibodies raised
against b-actin, c-fos and total or phosphorylated forms of IkBa
and ERK1/2 and HRP-conjugated anti-rabbit polyclonal anti-
body were from Cell Signaling Technology (MA, USA). Soluble
RANKL coupled to GST fusion protein (RANKL) was generously
provided by Drs Matthew Gillespie and Julian Quinn (Prince
Henry’s Institute, Monash Medical Centre, Melbourne, Australia).
Transcription factor activation kits incorporating detection
antibody for the p65 subunit of Nuclear Factor kappa B (NFkB)
and c-fos component of AP-1 were purchased from Pierce
Biotechnology (Illinois, USA). TransAM assay kits for Nuclear
factor of activated T-cells, cytoplasmic 1 (NFATc1) were from
Active Motif (California, USA).
Ethics statement
Human umbilical cord blood was obtained with written
informed consent from healthy donors under a protocol approved
by Barwon Health Human Research and Ethics Committee.
Mature human osteoclasts
Collection of human umbilical cord blood, isolation of a
mononuclear cell fraction, expansion of CFU-GM-derived OC
precursors and differentiation of mature human OCs have been
previously described [19]. Specifically, a mononuclear cell
fraction of cord blood (CBMC) was isolated by Ficoll-Paque
density gradient centrifugation. CBMCs (3610
6 cells/culture)
were suspended in 3.0 ml Methocult GF H4534 in 6-well plates
and incubated at 37C in humidified atmosphere of 5% CO
2-air
for 10 days. Pooled colonies (CFU-GM-derived OC precursors)
were harvested into PBS. Precursors (6.5610
6 cells/175 cm
2)
were then seeded into 175 cm
2 tissue culture flasks. The cells
were cultured in 20 mL of MEM containing 10% FBS,
nonessential amino acids, penicillin 50 U/ml, streptomycin
50 mg/ml, 2 mM L-glutamine, M-CSF (25 ng/ml), and RANKL
(125 ng/ml) for 14–21 days. The cultures were refreshed weekly
by replacing additives in one half volume of media. Mature OCs
were used in situ for signalling and transcription factor assays or
dissociated and re-settled on dentine slices for survival and
resorption assays.
Mature OC survival and resorption assay
Mature OC cultures were treated with dissociation buffer
(5 mL/75 cm
2 flask) for 30 min at 37C when most were detached
by agitation. Remaining adherent cells were removed with a cell
scraper. Detached OCs were washed, pelleted by centrifugation
(200 g; 2 min), resuspended in MEM/10% FBS and settled onto
round dentine slices (6 mm diameter) in 96-well plates (n=500–
1000 OCs/well) and cultured for 4–72 h in 200 mL of media.
Cells were fixed in 1% formalin and reacted for TRAP as
previously described [19]. The formation of OCs was assessed by
transmission light microscopy; quantified using microcomputer
image analysis software (MCID - Imaging Research Inc. Ontario,
Canada). F-actin stained sealing zones were quantified by confocal
microscopy using rhodamine-conjugated phalloidin [20]. Cells
were removed from dentine slices by brief sonication in
chloroform:methanol 2:1. Xylene-free black ink was applied to
the surface of each slice and residual ink removed by wiping on
absorbent paper. Resorption was assessed by reflective light
microscopy and the percentage area resorbed was quantified using
MCID software. This method was validated by comparison with
scanning electron microscopy [21].
NFkB, c-fos and NFATc1 transcription factor activity
Mature OC cultures in 6-well plates were rinsed, pre-treated
with or without M-CSF (37.5 ng/mL) for 18 h in MEM/
0.2%FBS and then treated with RANKL (125 ng/mL) or vehicle
for 30 min. Nuclear extracts (Ne-PER; Pierce, IL, USA) were
assessed for activation of NFkB(p65), c-fos and NFATc1 using
ELISA-based transcription factor assay kits. Briefly, an oligonu-
cleotide containing the consensus binding sequence for the
relevant transcription factor is immobilised to a 96-well plate.
Transcription factor contained in nuclear extracts binds specifi-
cally to this oligonucleotide and is detected through use of an
antibody directed against either p65, in the case of NFkB, c-fos or
NFATc1. Addition of a secondary antibody conjugated to
horseradish peroxidise provides sensitive chemiluminescent or
colorimetric readout that is quantified by spectrophotometry.
ERK1/2, IkBa signalling and c-fos Western Blot
Mature OCs in 25 cm
2 flasks were serum-starved for 18 h when
media was replaced with MEM/10%FBS with vehicle, RANKL
(125 ng/mL), M-CSF (25 ng/mL) or both. Cytoplasmic extracts
(M-PER, Pierce, IL, USA) were collected at 0, 5 min and 10 min.
For c-fos expression, mature OCs were treated with or without M-
CSF for 18 h before cell lysis. Total protein was subjected to SDS-
PAGE on 4–20% gradient gels (NuSep, Georgia, USA). Protein
gels were transferred to nylon membranes (Amersham Biosciences,
Buckinghamshire, UK) overnight at 4C (50 V; 25 mA) and
blocked in PBS containing 5%BSA; 0.2% Tween 20 for 1 h.
Immunodetection used primary rabbit monoclonal antibodies that
recognised either total or phosphorylated forms of IkBa, ERK1/2,
c-fos, or b-actin (Cell Signaling Technology, MA, USA).
Secondary antibody was HRP-conjugated anti-rabbit polyclonal
antibody (Cell Signaling Technology, MA, USA) A chemilumi-
nescent substrate followed by autoradiography was used for
detection (GE Healthcare Bio-Sciences, NJ, USA). MCID
software was used for densitometric analysis.
Statistical analyses
Data are expressed as the mean 6 SEM where applicable.
Differences between groups where determined using one-way
ANOVA followed by Fisher’s multiple comparison test, two-way
ANOVA – general linear model (GLM) followed by Tukey’s
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P,0.05. Treatment groups with annotations containing the same
letter are not significantly different. (For example: 3 groups
annotated with ‘‘a’’, ‘‘b’’ and ‘‘c’’, are all different to each other. In
the case of 3 groups annotated with ‘‘a’’, ‘‘ab’’ and ‘‘b’’, ‘‘a’’ is
different to ‘‘b’’, whereas ‘‘a’’ and ‘‘ab’’ are not different, likewise
‘‘ab’’ and ‘‘b’’.)
Results
M-CSF acutely augments RANKL-induced resorption in
mature human OCs
We assessed the survival and resorbing activity of mature
human OCs by seeding freshly harvested cells onto dentine slices
and culturing them for 72 h. Survival of OCs cultured in media/
10% FBS alone was enhanced (62% increase) by the addition of
M-CSF (25 ng/mL) but more effectively so (165% increase) by
RANKL (125 ng/mL). Neither M-CSF nor RANKL had any
substantial effect on OC plan area (size). In the absence of
RANKL, resorption was negligible. Activation of RANKL-
induced resorption per OC was markedly enhanced (300%
increase) by the addition of M-CSF (25 ng/mL) (Fig. 1A). In six
independent experiments, the addition of M-CSF (25 ng/mL)
resulted in a 220612% (mean6SEM) increase in resorption
compared to RANKL (125 ng/mL) alone (p=0.004, not shown).
This effect was concentration dependent (Fig. 1B). At M-CSF
concentrations between 50 and 200 ng/mL, a concentration-
dependent, although non-significant, trend to decreased resorption
was apparent. In cultures treated with RANKL only, co-treatment
with a neutralising antibody to M-CSF had no significant effect on
survival or resorption, indicating that endogenous M-CSF [11] is
not necessary for RANKL-induced survival or resorption
activation (Fig. 1B). A 130% stimulation of resorption in the
presence of M-CSF (37.5 ng/mL) was accompanied by an
Figure 1. M-CSF augments RANKL-induced resorption and F-actin sealing zone formation by harvested OCs. Mature OCs were formed
from CFU-GM precursors cultured on plastic in the presence of RANKL (125 ng/mL) and M-CSF (25 ng/mL) for 21 d. Mature OCs were then detached
with non-enzymatic dissociation buffer, re-adhered to dentine slices and cultured for a further 72 h. (A) Survival and activity of harvested OCs
cultured in media alone or combinations of RANKL (125 ng/mL) and M-CSF (25 ng/mL); data representative of 6 independent experiments. (B)
Concentration-dependent stimulation of RANKL-induced resorption by M-CSF; data representative of 3 independent experiments. RANKL (125 ng/ml)
added to all cultures. (C) M-CSF (25 ng/mL) potentiates RANKL-induced (125 ng/mL) sealing zone formation. (D) Photomicrographs show OCs stained
for F-actin. Results expressed as mean 6 SEM (n=6 dentine slices/group). Groups with different annotations are significantly different; Panel A&B
p=0.001; one-way ANOVA; Fishers multiple comparison test; Panel C p=0.001; Two-sample T-test.
doi:10.1371/journal.pone.0021462.g001
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treatment with RANKL alone (Figs. 1C and 1D).
In our 72 h cultures, we could not exclude the possibility that
the observed resorption-stimulating effect was due to ongoing OC
differentiation in the presence of M-CSF. In CFU-GM osteoclas-
togenesis cultures we previously found a linear increase in OC
plan area over three weeks due to progressive cell fusion [19] yet in
the current study, no substantive increase in OC plan area was
observed with M-CSF, suggesting an absence of significant cell
fusion. Nevertheless, to exclude this possibility, we conducted
experiments over a shorter time of 4–24 h. Since the small amount
of dentine resorption present in these short-term assays could not
be accurately quantified using whole-slice image analysis, we
counted resorption pits at higher magnification and individually
measured their plan area and diameter or, in the case of non-
circular ‘‘trail or trench’’ pits, trail pit linear length (trail length). In
these experiments, OCs were treated with RANKL (125 ng/mL)
alone or together with M-CSF (25 ng/mL) (Figs. 2A and 2B). No
significant effect on OC number was seen over this period. In the
presence of RANKL only, the resorption pit number, size and trail
length increased with time in a linear manner. Co-treatment with
M-CSF increased the pit number and pits per OC at each time
point (200% at 24 h) but had no substantive effect on the pit size
or trail length (Fig. 2A). The effect of M-CSF at 6 h in an
independent experiment is shown in Fig. 2B. The addition of
M-CSF to RANKL had no effect on OC characteristics but
increased the number of pits and pits per OC by 66% and 62%,
respectively.
M-CSF pre-treatment facilitates RANKL-induced
activation of c-fos but not of NFkB
In mature human OCs, NFATc1 is not activated by either
RANKL or M-CSF. Acute treatment with RANKL of OCs that
had been serum-starved for 18 h produced a 320% activation of
NFkB at 30 min (Fig. 3A). Pre-treatment with M-CSF (37.5 ng/
mL) for 18 h had no effect on basal or RANKL-induced activation
of NFkB (Fig. 3A). In contrast, in control OCs, RANKL did not
activate c-fos, whereas pre-treatment with M-CSF increased basal
activation by 70% and RANKL-induced activation by 190%
(Fig. 3A). We also found that M-CSF pre-treatment increased
basal c-fos protein expression by 41.5% (Fig. 3B). No effect on
NFATc1 activation was seen with M-CSF pre-treatment or acute
RANKL treatment (Fig. 3A).
Phosphorylation of ERK1/2 by M-CSF is augmented by
co-treatment with RANKL in mature human OCs
Since MEK/ERK pathways are known to be involved in both
RANK and c-fms signalling [22–24], we hypothesised that they
may be involved in the observed effect of M-CSF on RANKL-
Figure 2. M-CSF rapidly potentiates RANKL-induced resorption by harvested OCs. Mature OCs were re-adhered to dentine slices and
cultured for up to 24 h in RANKL (125 ng/mL) alone or RANKL (125 ng/mL) + M-CSF (25 ng/mL). A. Time course of OC survival and resorption. Results
expressed as mean 6 SEM (n=6 dentine slices/group). Groups with different annotations (a,b,c) are significantly different for treatment; P,0.05
ANOVA GLM Tukey pairwise comparisons. Groups with different annotations (x,y,z) are significantly different for time; P,0.003 ANOVA GLM Tukey
pairwise comparisons; data from one experiment. B. Potentiation of OC activity by M-CSF (25 ng/mL) at 6 h of treatment. Results expressed as mean
6 SEM (n=6 dentine slices/group). P,0.05 Two-sample T-test; data from one experiment.
doi:10.1371/journal.pone.0021462.g002
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is well characterised [25,26] and in the current study we have
shown that c-fos is activated by M-CSF. In serum-starved OCs we
found no detectable levels of constitutively phosphorylated ERK1/
2. Treatment with M-CSF activated phosphorylation, with a peak
increase of 477% at 5 min, dissipating to 70% at 10 min (Fig. 4A).
Treatment with RANKL produced only a weak phosphorylation
of ERK1/2 at 5 min, in comparison to M-CSF, with negligible
levels detected at 10 min. Co-treatment with RANKL and M-CSF
increased ERK1/2 phosphorylation at 5 min (44% increase) and
10 min (+19%), compared to M-CSF alone. Levels of total
ERK1/2 were unchanged over the time-course investigated.
M-CSF alone decreased phosphorylated IkBa by 42% at
10 min, whereas RANKL exposure stimulated phosphorylation by
278%. There was no additional effect in combination with M-
CSF. Total IkBa was unchanged over the time-course (Fig. 4B).
Blockade of MEK/ERK signalling inhibits M-CSF-induced
stimulation of resorption
The results above indicated that ERK1/2 phosphorylation was
enhanced by co-treatment with M-CSF and RANKL, suggesting
that MEK/ERK signalling may be involved in M-CSF enhance-
ment of RANKL-induced resorption activity. To test this
possibility, we examined the effects of PD98059, a specific
inhibitor of the ERK1/2 activator MEK-1, on this effect. Mature
OCs cultured on dentine slices were pre-treated for 1 h with
PD98059 (5 mM), or vehicle, prior to treatment with RANKL
alone or together with M-CSF for 72 h. Pre-treatment with
PD98059 had no effect on OC survival, size or RANKL-induced
resorption (Fig. 5). In cultures pre-treated with vehicle, treatment
with RANKL and M-CSF produced a 330% increase in
resorption compared to RANKL alone. This effect was attenuated
in the presence of PD98059. In the experiment shown in Fig. 5,
resorption in M-CSF group is not significantly different (ANOVA)
to that of the RANKL-only control in the presence of PD98059.
However, in 3 independent experiments PD98059 reduced the
resorption-stimulating effect of M-CSF by 52.366.2% but
resorption in the M-CSF group remained significantly greater
than the control (p=0.023, paired T-test).
Discussion
Utilising a human, mature OC activation assay, we have
demonstrated that M-CSF effectively activates OC resorption, in
Figure 3. M-CSF pre-treatment facilitates RANKL-induced activation of c-fos but not of NFkB. NFATc1 is not activated by either RANKL or
M-CSF. Mature human OCs cultured in 6-well plates for 21 d were serum-starved for 18 h in the absence or presence of M-CSF (37.5 ng/mL) followed
by stimulation with RANKL (125 ng/mL) for 30 min. A. Relative activation of transcription factors quantified using ELISA-based transcription factor
activation assays: NFkB(p65 subunit) and c-fos (Pierce Biotechnology, USA); NFATc1 (Active Motif, USA); representative data from 2 independent
experiments. Results expressed as mean 6 SEM (n=3 wells/group). Groups with different annotations are significantly different; p=0.001; one-way
ANOVA; Fishers multiple comparison test. B. Western analysis of c-fos protein; mature OCs cultured for 18 h in media alone, with or without M-CSF
(25 ng/mL).
doi:10.1371/journal.pone.0021462.g003
M-CSF Augments Resorption by Human Osteoclasts
PLoS ONE | www.plosone.org 5 June 2011 | Volume 6 | Issue 6 | e21462addition to its roles in survival and motility. It is established that
RANKL rapidly activates resorption in isolated mouse OCs [27],
increasing actin-ring formation within 30 minutes. Furthermore,
treatment of mice with intravenous RANKL increases ionized
calcium at 1 h, consistent with acute activation of mature OCs
[27]. In our system, exposure to RANKL alone initiates, within
4 h, the formation of resorption pits that progressively enlarge with
time, while the addition of M-CSF results in a rapid increase in the
relative number of pits, which are not larger or longer, indicating a
fundamental difference in the mechanism. The rapidity of this
effect suggests that it is not due to an effect on OC differentiation
but, rather, activation of mature cells. Pits progressively accumu-
late so the increased number could be due to an increase in the
proportion of OCs activated to form pits, or an increase in the
activation frequency among the same proportion of the OCs.
However, since the presence of an actin ring indicates current OC
activation [28], the observed increase in sealing zone number
confirms that the increased pit number is due to a greater
proportion of activated OCs.
Functional RANK is expressed on mature OCs and RANKL
stimulates their activation [27,29,30]. Since resorption is
RANKL-dependent, we surmised that augmentation of RANK
signalling by M-CSF was a possible mechanism of its stimulation
of OC activation. In OC precursors, a number of signalling
cascades are known to be activated downstream of RANK
leading to activation of NFkB, AP-1, p38, ERK, Src and NFAT
(reviewed by Boyle et al. [12]). However, most of this knowledge
is based on investigations done in rodent osteoclast generation
models and the signalling pathways involved in the activation of
mature OCs have not been well characterised. Likewise,
signalling downstream of c-fms, the tyrosine kinase receptor of
M-CSF is not well characterised in mature OCs although the
important roles of Src kinase in resorption [31,32], PI-3-kinase in
motility [33] and PI-3-kinase as well as MEK 1 in survival [34]
are well established. Therefore, we investigated the effects of
acute treatment of OCs with RANKL on activation of NFkB, c-
fos and NFATc1, and the modulation of this by M-CSF. In fully
differentiated OCs under these experimental conditions, RANKL
activation of NFkB is independent of M-CSF. However, RANKL
activation of c-fos is dependent on the presence of M-CSF.
NFATc1 appears to have no role in RANKL-induced activation
of differentiated OCs. These results are consistent with the results
of our resorption assays where RANKL initiates sub-maximal
resorption activity independent of M-CSF while M-CSF
augments RANKL-induced resorption, the former mediated by
NFkB and the latter by c-fos.
Yao et al. [35] have previously shown that M-CSF treatment of
mature mouse OCs results in increased c-fos expression and
transcriptional activation [35]. The key role of c-fos in OC
differentiation is well established [36,37]. Our results indicate that
in mature OCs c-fos activation is not essential for the initiation of
resorption but that its activation by M-CSF greatly augments
RANKL-induced activation of resorption. Moreover, although
NFATc1 is critical in osteoclast differentiation it appears to play
no part in resorption activation of fully differentiated OCs. Lee
and Kim [26] have previously highlighted that existing data show
that signalling pathways stimulated by RANKL are different in
OC precursors and mature OCs [26].
Miyazaki et al. [24] used adenoviral gene transfer methods to
activate and inhibit ERK and NFkB in semi-pure mouse OC
cultures. Activation of ERK increased OC survival and inhibition of
ERK decreased survival but neither had any effect on their bone-
resorbing activity. In contrast, activation and inhibition of NFkB
increased and decreased OC resorbing activity, respectively, but had
no effect on survival [24]. We have shown that in fully differentiated
human OCs, functional MEK/ERK pathways are not essential for
the pro-survival and pro-resorption effects of RANKL but these
pathways are involved in M-CSF augmentation of RANKL-induced
resorption activation. The involvement of ERK is consistent with the
involvement of c-fos activation that we have demonstrated. The
results do not exclude the possibility that other MAPK parallel
cascades, such as JNK and p38 are also involved [25].
Our novel finding that M-CSF regulates the rate of osteoclastic
bone resorption in vitro, independent of OC formation, is supported
by data from two murine in vivo studies. The first investigated the
capacity of cell-surface M-CSF (csCSF-1) to restore in vivo M-CSF
function in the CSF-1-deficient osteopetrotic (Csf1
op/Csf1
op) back-
ground [6]. Transgenic expression of csCSF-1 corrected the gross
defects of these mice, including growth retardation and failure of
tooth eruption. However, residual osteopetrosis and significantly
delayed trabecular bone resorption in the subepiphyseal region of
the long bones, along with incomplete correction of hematologic
abnormalities were found. Complete restoration was achieved by
transgenic expression of the full length CSF-1 gene, which encodes
both circulating CSF-1 and some csCSF-1 [38]. Only partial
correction of osteopetrosis in csCSF-1 transgenic mice was
observed, even though there was an equivalent number and size
of OCs to wild-type controls. This finding prompted the authors to
conclude that while local csCSF-1 expression was sufficient to
support osteoclastogenesis, the rate of bone resorption in these
animals lacking circulating M-CSF was slower [6]. These
investigators subsequently demonstrated [7] that the osteopetrosis
phenotypeofCSF-1-andCSF1R-deficientmicecould be replicated
by post-natal administration of a neutralising anti-CSF-1 antibody.
The number of OCs was dramatically reduced at 15.5 but not at
36.5 or 64.5 days post-natal, and increased trabecular bone density
remained. Very low to undetectable levels of circulating antibody
were present in the older mice, suggesting that some M-CSF was
present (although not measured in this study) but at sub-optimal
levels for OC resorption to proceed [7].
Figure 4. Activation of ERK1/2 and IkBa by RANKL and M-CSF
in mature OCs. Mature OCs were serum starved for 18 h then acutely
treated with RANKL (125 ng/mL) or M-CSF (25 ng/mL) alone, or in
combination. Cytoplasmic protein extracts were harvested and
subjected to SDS-PAGE followed by western analysis utilising antibodies
against total and phosphorylated ERK1/2 and IkBa. A. Augmentation of
phospho-ERK1/2 in the presence of RANKL and M-CSF. B. M-CSF has no
effect on phospho-IkBa; representative data from 2 independent
experiments.
doi:10.1371/journal.pone.0021462.g004
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mately 12 ng/mL in the early twenties to 20 ng/mL in the eighties,
corresponding to the concentration range where we observed in vitro
a three- to four-fold increase in resorption [39]. In women, the
serum bone resorption marker, C-telopeptide, increases in a near
linear manner from age 21 to 71 years and bone mineral density
declines substantially with ageing [40]. Thus, the possibility exists
that increasing circulating M-CSF is involved in ‘‘normal’’ age-
related bone loss. Furthermore, as we have previously reviewed,
systemic and/or local M-CSF concentrations are increased in a
variety of inflammatory and neoplastic conditions known to be
associated with bone loss [11].
Karsdal et al. [41] pointed out that osteopetrotic mutations
resulting in reduced or absent OCs are associated with decreased
bone formation, whereas osteopetrotic mutations that result in
increased numbers of non-resorbing OCs are associated with
increased bone formation and suggested that nonresorbing osteoclasts
provide anabolic signals for osteoblasts [41]. It has subsequently been
shown that secreted products of OCs, spingosine-1-phosphate and
bone morphogenic protein 6 stimulate migration and osteoblast
differentiation of human mesenchymal stem cells [42].
We hypothesize that incomplete blockade of c-fms signalling, or
downstream signalling pathways, may provide a potential means
to attenuate bone loss. In this situation, OC differentiation will
proceed but the proportion activated to resorb will be lower,
resulting in reduced bone resorption yet maintenance of OC-
derived anabolic signals to osteoblasts.
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